EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).

AT-19 is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Chronic Lymphocytic Leukemia (CLL).

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia ... risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received ...

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple ...

Blood stem cell transplants have been central players in treating blood cancers ... There are some cancer types where ...

This page includes links to articles highlighting the top hematologic cancer research published on Cancer Therapy Advisor in ...

Although everyone’s CLL journey is different, there tend to be shared milestones that can give patients a sense of progress, ...

Here are nine tips to help you manage chronic lymphocytic leukemia (CLL ... catching an infection because it damages the white blood cells that help your body fight off germs.

Chronic Lymphocytic Leukemia In the early stages of chronic lymphocytic leukemia (CLL), a period ... These drugs target a protein (CD20) found on the surface of B cells. There is a wide range of ...

Dr. Ruemu Birhiray explains chronic myeloid leukemia (CML), its treatment options, and what patients should know about this ...